Multiple Myeloma Case Developed During the Use of the Teriparatide
Recombinant human parathyroid hormone (1-34) (rhPTH 1-34), teriparatide, is a class of anabolic therapy for treating severe osteoporosis. Although plasma cell dyscrasias are excluded among the known side effects of teriparatide treatment, their association in the form of case reports has been report...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Yayinevi
2022-04-01
|
| Series: | Türk Osteoporoz Dergisi |
| Subjects: | |
| Online Access: |
http://www.turkosteoporozdergisi.org/archives/archive-detail/article-preview/multiple-myeloma-case-developed-during-the-use-of-/51345
|